Dermatology Billing: The Measurement Rule Costing Practices Thousands

Dermatology denial rates run 14-20%, well above the broader industry average, driven by procedurally dense visits where a single appointment can generate a biopsy, a destruction, and an excision in one session. Most of the revenue loss comes down to a small number of specific, fixable patterns — starting with a measurement timing rule that alone costs a typical practice $12,000-$20,000 a year.

Measure first, cut second

CPT instructions are explicit: code selection for lesion excision is determined by measuring the greatest clinical diameter of the lesion plus the narrowest margin required for complete excision — and that measurement has to happen before the lesion is excised, not after. The reason is physical, not procedural: once the incision releases the tension holding the surrounding skin in place, the lesion site contracts. A lesion measured after excision will consistently read smaller than its true pre-excision size, and that difference is often enough to drop the claim into a lower-paying code tier.

Worked example: a 1.2 cm basal cell carcinoma excised with 0.4 cm margins on each side produces an excised diameter of 2.0 cm (1.2 + 0.4 + 0.4), not the 1.2 cm lesion measurement alone. Documenting only the lesion diameter, without explicitly adding the margin on each side, is the single most common cause of excision undercoding — and for a practice performing 200-300 excisions a year, that gap alone represents an estimated $12,000-$20,000 in annual lost revenue. The fix is a one-line addition to the operative note template: lesion diameter, margin width on each side, and an explicit note that the measurement was taken prior to local anesthetic administration.

Biopsy codes are technique-based, not site-based

CMS restructured the skin biopsy code family effective January 1, 2019, and the change still trips up practices that haven't fully adapted their documentation workflows. Code selection depends on how the biopsy was performed — tangential (shave), punch, or incisional — not where on the body it was taken from.

2026 updates tightened this further: the technique used now needs to be explicitly identified in the procedure note itself, not just on the pathology requisition form — which is not part of the medical record for billing purposes. A note that simply says "biopsy performed" without naming the technique is now at meaningfully higher documentation risk than it was even a year ago.

Biopsy vs excision: never interchangeable

A biopsy removes a sample of tissue for diagnostic purposes; an excision removes the entire lesion. These are structurally different procedures with entirely separate CPT code families, and coding one as the other — in either direction — produces incorrect reimbursement and creates genuine compliance exposure under audit. When both a biopsy and a complete excision happen to the same lesion in the same session, only the excision code is billed; the biopsy is not separately payable in that scenario. When multiple distinct lesions are excised in the same session, each is coded and billed separately, with modifier 59 (or the more specific X-modifiers) appended to the second and subsequent excision codes at the same anatomic location to prevent the claim from being automatically bundled and denied.

The Mohs pathology bundling trap

Mohs micrographic surgery is the highest-reimbursement, highest-complexity procedure in dermatology billing, and one specific bundling error recurs constantly: billing CPT 88305 (surgical pathology) separately for tissue that was examined as part of the Mohs procedure itself. The pathology work for that tissue is already included in the Mohs codes (17311-17314) — submitting 88305 alongside them for the same tissue is a guaranteed denial, not a gray area. Separate pathology billing is appropriate only for tissue that genuinely goes to an outside pathologist, such as permanent sections of the deep margin processed after the Mohs procedure is complete. Reconstruction following Mohs is billed separately using the appropriate repair codes — the repair is not included in the Mohs codes and needs its own operative documentation distinct from the Mohs stages themselves.

Modifier 25 on same-day E/M

When a dermatologist evaluates a new or changed condition and performs a procedure in the same visit, modifier 25 on the E/M code is what allows both to be paid — but the E/M has to be genuinely separate and significant, not just the routine evaluation that leads into a planned biopsy on a previously identified lesion. If a patient returns specifically for a biopsy of a lesion already identified at a prior visit, that visit's E/M component is typically not separately billable; modifier 25 only applies when something distinct from the procedure itself was evaluated and documented. Missing modifier 25 on visits that do qualify for it is estimated to cost practices $15,000-$40,000 annually — a gap purely in claim construction, not clinical work performed.

Are your excision measurements happening too late?

A free billing audit shows exactly where measurement timing, biopsy technique documentation, and modifier gaps are costing your dermatology practice revenue.